1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
May 2025 in “LUMEN ET VIRTUS” Nursing care is crucial for safe and effective hair transplants.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
June 2023 in “Dermatology and therapy” The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
7 citations
,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata.
August 2025 in “Acta Dermato Venereologica” 2 citations
,
September 2025 in “Journal of Dermatological Treatment” Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
September 2022 in “Plastic and Reconstructive Surgery” Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.